REGENERON PHARMACEUTICALS, INC. Inventory, Raw Materials, Net of Reserves
REGENERON PHARMACEUTICALS, INC. (REGN) had Inventory, Raw Materials, Net of Reserves of $610.90 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative
us-gaap:InventoryRawMaterialsNetOfReserves · last filed 2026-07-30
- 2026-06-30: Inventory, Raw Materials, Net of Reserves $610.90M.
- 2026-03-31: Inventory, Raw Materials, Net of Reserves $630.70M.
- 2025-12-31: Inventory, Raw Materials, Net of Reserves $641.50M.
- 2025-09-30: Inventory, Raw Materials, Net of Reserves $710.00M.
| Period end | Inventory, Raw Materials, Net of Reserves | Inventory, Raw Materials, Net of Reserves as first filed |
|---|---|---|
| 2026-06-30 | $610.90M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $630.70M 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $641.50M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $710.00M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $752.30M 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $838.50M 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $879.50M 10-K · filed 2026-02-04 | |
| 2024-09-30 | $856.60M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $843.60M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $814.80M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $789.30M 10-K · filed 2025-02-05 | |
| 2023-09-30 | $787.30M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $813.30M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $844.60M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $818.40M 10-K · filed 2024-02-05 | |
| 2022-09-30 | $920.90M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $831.70M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $773.50M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $721.90M 10-K · filed 2023-02-06 | |
| 2021-09-30 | $646.30M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $601.50M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $576.20M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $459.40M 10-K · filed 2022-02-07 | |
| 2020-09-30 | $400.40M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $306.30M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $210.90M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $216.30M 10-K · filed 2021-02-08 | |
| 2019-09-30 | $229.00M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $229.70M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $232.40M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $226.80M 10-K · filed 2020-02-07 | |
| 2018-09-30 | $216.67M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $205.46M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $201.43M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $190.00M 10-K · filed 2019-02-07 | $190.04M 10-K · filed 2018-02-08 |
| 2017-09-30 | $187.03M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $170.27M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $127.64M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $92.29M 10-K · filed 2018-02-08 | |
| 2016-09-30 | $89.67M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $73.97M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $85.18M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $59.15M 10-K · filed 2017-02-09 | |
| 2015-09-30 | $34.98M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $21.00M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $9.64M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $10.92M 10-K · filed 2016-02-11 | |
| 2014-09-30 | $10.17M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $10.22M 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $6.79M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $9.12M 10-K · filed 2015-02-12 | |
| 2013-09-30 | $5.22M 10-Q · filed 2013-11-05 | |
| 2013-06-30 | $5.38M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $6.32M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $4.86M 10-K · filed 2014-02-13 | |
| 2011-12-31 | $4.67M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |